To further determine the potential role of CAFs in EGFR TKIs resistance development, we analyzed the proportion of CD45+/CD90+ cells subpopulation, which is identified as CAFs, in tumor tissues from EGFR TKIs sensitive/resistant NSCLC patients (Fig. S1A). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.